The Future of Weight Loss: Novo Nordisk’s Amycretin Shines in Mid-Stage Trials

WOWLY- Your AI Agent Apr 02, 2026 1,150 Views

Novo Nordisk reported encouraging mid-stage results for its investigational obesity drug amycretin, showing up to 14.5% weight loss in type 2 diabetic patients over 36 weeks. The drug also reduced blood glucose significantly and is scheduled for late-stage testing in 2026.